BR9908178A - Processos para tratamento de diabetes usando análogos peptìdios de insulina - Google Patents

Processos para tratamento de diabetes usando análogos peptìdios de insulina

Info

Publication number
BR9908178A
BR9908178A BR9908178-4A BR9908178A BR9908178A BR 9908178 A BR9908178 A BR 9908178A BR 9908178 A BR9908178 A BR 9908178A BR 9908178 A BR9908178 A BR 9908178A
Authority
BR
Brazil
Prior art keywords
peptide analogs
processes
treating diabetes
insulin peptide
insulin
Prior art date
Application number
BR9908178-4A
Other languages
English (en)
Inventor
Amitabh Gaur
Nicholas Ling
Paul J Conlon
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of BR9908178A publication Critical patent/BR9908178A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"PROCESSOS PARA TRATAMENTO DE DIABETES USANDO ANáLOGOS PEPTìDIO DE INSULINA". A presente invenção é direcionada a análogos peptídios de cadeia (B) de insulina que são genericamente derivados de peptídios compreendendo resíduos (9 a 23) da sequência de cadeia (B) nativa. Os análogos são alterados da sequência nativa na posição (12, 13, 15) e/ou (16), e podem ser adicionalmente alterados na posição (19) e/ou outras posições. Composições farmacêuticas contendo estes análogos peptídios são providas. Os análogos peptídios são úteis para tratamento e inibição de desenvolvimento de diabetes.
BR9908178-4A 1998-02-23 1999-02-23 Processos para tratamento de diabetes usando análogos peptìdios de insulina BR9908178A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2815698A 1998-02-23 1998-02-23
PCT/US1999/003915 WO1999042482A1 (en) 1998-02-23 1999-02-23 Methods for treatment of diabetes using peptide analogues of insulin

Publications (1)

Publication Number Publication Date
BR9908178A true BR9908178A (pt) 2002-01-15

Family

ID=21841884

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908178-4A BR9908178A (pt) 1998-02-23 1999-02-23 Processos para tratamento de diabetes usando análogos peptìdios de insulina

Country Status (20)

Country Link
US (1) US6197926B1 (pt)
EP (1) EP1056776A1 (pt)
JP (1) JP2002504491A (pt)
KR (1) KR20010041238A (pt)
CN (1) CN1241942C (pt)
AP (1) AP2000001888A0 (pt)
AU (1) AU741037B2 (pt)
BR (1) BR9908178A (pt)
CA (1) CA2321929A1 (pt)
EA (1) EA003944B1 (pt)
HU (1) HUP0100928A3 (pt)
ID (1) ID26788A (pt)
IL (1) IL137904A0 (pt)
NO (1) NO20004198L (pt)
NZ (1) NZ506447A (pt)
OA (1) OA11453A (pt)
PL (1) PL342517A1 (pt)
SK (1) SK12412000A3 (pt)
TR (1) TR200003048T2 (pt)
WO (1) WO1999042482A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562942B1 (en) 1999-02-23 2003-05-13 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US7371385B2 (en) * 2000-05-12 2008-05-13 Oregon Health & Science University Method of treating immune pathologies with low dose estrogen
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
US20070172453A1 (en) * 2002-08-30 2007-07-26 Vincent Geenen Tolerogenic approach for type 1 diabetes
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
EP1551495A4 (en) 2002-10-10 2010-06-02 Yeda Res & Dev BASIC ESTERS OF FAT ALCOHOLS AND THEIR USE AS ANTI-INFLAMMATORY OR IMMUNOMATORY AGENTS
EP1660110A2 (en) * 2003-06-02 2006-05-31 Mercia Pharma, Inc. Therapeutic vaccine compositions for the treatment of type 1 diabetes
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP2229407B1 (de) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
JP5789515B2 (ja) * 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2011058082A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
US20110311536A1 (en) * 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
EP2585102B1 (en) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013096386A1 (en) 2011-12-20 2013-06-27 Indiana University Research And Technology Corporation Ctp-based insulin analogs for treatment of diabetes
JP6387008B2 (ja) 2012-09-26 2018-09-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリンアナローグダイマー
RU2678134C2 (ru) 2013-03-14 2019-01-23 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты инсулин-инкретин
ES2947409T3 (es) 2014-09-24 2023-08-08 Univ Indiana Res & Tech Corp Profármacos de insulina a base de amida lipídica
EP3206710B1 (en) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates
PL3229828T3 (pl) 2014-12-12 2023-07-31 Sanofi-Aventis Deutschland Gmbh Formulacja o ustalonym stosunku insuliny glargine/liksysenatydu
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN111925420B (zh) * 2019-12-11 2022-04-01 山东大学 一种多肽作为嗅觉受体Olfr109激动剂配体的应用
USD1043348S1 (en) * 2021-09-24 2024-09-24 H.J. Heinz Company Brands Llc Bottle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5559094A (en) 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5594100A (en) * 1995-02-22 1997-01-14 Regents Of The University Of Colorado Epitope for prevention of type I diabetes
EP0835129B1 (en) * 1995-06-30 2003-10-29 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes

Also Published As

Publication number Publication date
NO20004198D0 (no) 2000-08-22
AP2000001888A0 (en) 2000-09-30
EA200000872A1 (ru) 2001-02-26
AU2783199A (en) 1999-09-06
CN1294597A (zh) 2001-05-09
WO1999042482A1 (en) 1999-08-26
JP2002504491A (ja) 2002-02-12
EP1056776A1 (en) 2000-12-06
CA2321929A1 (en) 1999-08-26
PL342517A1 (en) 2001-06-18
HUP0100928A2 (hu) 2001-08-28
SK12412000A3 (sk) 2002-05-09
ID26788A (id) 2001-02-08
TR200003048T2 (tr) 2000-12-21
KR20010041238A (ko) 2001-05-15
NO20004198L (no) 2000-10-20
HUP0100928A3 (en) 2001-11-28
CN1241942C (zh) 2006-02-15
NZ506447A (en) 2002-11-26
EA003944B1 (ru) 2003-10-30
US6197926B1 (en) 2001-03-06
OA11453A (en) 2003-12-08
IL137904A0 (en) 2001-10-31
AU741037B2 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
BR9908178A (pt) Processos para tratamento de diabetes usando análogos peptìdios de insulina
ATE266043T1 (de) Peptidanaloge des menschlichen basischen myelinproteins
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
BR9714200A (pt) Análogos de hormÈnio paratiróide
DE69027989D1 (de) Il-3 MIT ZUSÄTZLICHEN CYSTEINRESTEN UND CHEMISCHE MODIFIKATIONEN DAVON
PT93832A (pt) Processo para a preparacao de analogos de insulina hepatospecificos e de composicoes farmaceuticas que os contem
GR77934B (pt)
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DK165988C (da) Modificerede egliner b og c, deres anvendelse som proteaseinhibitorer, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende de modificerede egliner b og c
ATE121755T1 (de) Deletionsanaloga von magaininpeptiden.
HUP0000432A2 (hu) Inzulin C-peptidek
ATE273997T1 (de) Zyklische hexapeptid somatostatin analoga
ES2010283A6 (es) Procedimiento para preparar derivados de somatostatina.
DE69029377D1 (de) Substituierungsanaloge von magaininpeptiden
BR9307687A (pt) Análogos de insulina
Kobayashi et al. The primary structure of a new Mr 18,000 calcium vector protein from amphioxus.
DK527187A (da) Gonadoliberin-analoge, fremgangsmaade til deres fremstilling samt deres anvendelse som laegemidler
PT659883E (pt) Proteina p140 e adn que a codifica
Boulton et al. The third variant of human myoglobin showing an unusual amino acid substitution: 138 (H16) arginine→ tryptophan
DE69534596D1 (de) Epil/plazentin
HUP0100132A2 (hu) A béta-lipotropin és felhasználása
AR004497A1 (es) Un análogo hexapéptido cíclico de somatostatina, procedimiento para prepararlos y las composiciones farmacéuticas que los contienen y el uso de dicho hexapéptido para la preparación de una composición farmacéutica.
DK436187D0 (da) Polypeptider med hypocalcemivirkning og fremgangsmaade til fremstilling deraf samt laegemidler med indhold deraf
ES2141795T3 (es) Procedimiento de preparacion de ureinas derivadas de alfa,omega-diaminoacidos.
GB2123836A (en) Use of peptides as a medicament

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1990 DE 25/02/2009.